Cochrane · systematic review · CD007927
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
Morrison, J, Thoma, C, Goodall, RJ, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
18
No studies
2
Included studies
NR
No studies 2 · 10%Ungraded 0 · 0%Very low 8 · 40%Low 9 · 45%Moderate 1 · 5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
EGFR tyrosine kinase inhibitor (TKI) compared to observation alone for maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy
Population: maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival EGFR tyrosine kinase inhibitor (TKI) vs observation alone | HR 0.99 [0.81, 1.2] | 1 study · 835 participants | Low Downgraded: imprecision, inconsistency |
Progression‐free survival EGFR tyrosine kinase inhibitor (TKI) vs observation alone | HR 1.05 [0.9, 1.23] | 1 study · 835 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life EGFR tyrosine kinase inhibitor (TKI) vs observation alone | no estimate extracted | 1 study · 835 participants | Very low Downgraded: risk of bias, imprecision |
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer
Population: treatment of relapsed epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | HR 1.25 [0.8, 1.95] | 1 study · 129 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | HR 0.99 [0.69, 1.42] | 1 study · 129 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Toxicity: grade 3 or 4 rash EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | RR 13.63 [0.78, 236.87] | 1 study · 125 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Toxicity: grade 3 or 4 nausea ± vomiting EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | RR 0.63 [0.16, 2.52] | 1 study · 125 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Toxicity: grade 3 or 4 fatigue EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | RR 0.87 [0.28, 2.72] | 1 study · 125 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Toxicity: cardiac toxicity (any grade) EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | RR 5.24 [0.26, 107.02] | 1 study · 125 participants | Low Downgraded: imprecision |
Quality of life: not measured EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |
Anti‐EGFR antibody plus chemotherapy compared to chemotherapy alone for treatment of relapsed epithelial ovarian cancer
Population: treatment of relapsed epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | HR 0.93 [0.74, 1.18] | 4 studies · 658 participants | Moderate Downgraded: risk of bias, imprecision |
Progression‐free survival Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | HR 0.9 [0.7, 1.16] | 4 studies · 658 participants | Low Downgraded: risk of bias, imprecision |
Toxicity: grade 3 to 4 anaemia Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 0.84 [0.47, 1.49] | 4 studies · 652 participants | Low Downgraded: risk of bias, imprecision |
Toxicity: grade 3 or 4 diarrhoea Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 2.87 [0.59, 13.89] | 4 studies · 652 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Toxicity: grade 3 or 4 diarrhoea ‐ pertuzumab Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 6.37 [1.89, 21.45] | 3 studies · 432 participants | Low Downgraded: risk of bias, imprecision |
Toxicity: grade 3 or 4 diarrhoea ‐ seribantumab Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 0.38 [0.07, 2.23] | 1 study · 220 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Toxicity: grade 3 or 4 nausea ± vomiting Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 1.27 [0.56, 2.89] | 3 studies · 503 participants | Low Downgraded: risk of bias, imprecision |
Toxicity: grade 3 or 4 fatigue Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 1.06 [0.66, 1.73] | 4 studies · 652 participants | Low Downgraded: risk of bias, imprecision |
Toxicity: grade 3 or 4 hypokalaemia Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | RR 2.01 [0.8, 5.06] | 3 studies · 522 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone | no estimate extracted | NR | No studies |